Tokyo, June 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057875) titled 'Predictive method for assessing the efficacy of tarlatamab' on May 26
Study Type:
Observational
Study Design:
Primary Sponser:
Institute - Osaka International Cancer Institute
Condition:
Condition - Small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Intervention:
Eligibility:
Age-lower limit - 20
years-old
Gender - Male and Female
Key inclusion criteria - Pathologically diagnosed as small cell lung cancer.
Scheduled to undergo tarlatamab therapy.
Provided informed consent.
Key exclusion criteria - Deemed inappropriate by the attending physician.
Target Siz...